Homozygous familial hypercholesterolemia: Phenotype rules!

Atherosclerosis

Volumn 248, Issue , 2016, Pages 252-254

  Santos, Raul D ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Atherosclerosis; Cholesterol; Familial hypercholesterolemia; Genotype; Phenotype

Indexed keywords

APOLIPOPROTEIN B; BILE ACID SEQUESTRANT; EVOLOCUMAB; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KEXIN; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MIPOMERSEN; NICOTINIC ACID; PROPROTEIN CONVERTASE KEXIN TYPE 9; UNCLASSIFIED DRUG;

AORTA VALVE DISEASE; ATHEROSCLEROSIS; CARDIOVASCULAR MORTALITY; CHOLESTEROL BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG TOLERABILITY; FAMILIAL HYPERCHOLESTEROLEMIA; GENE MUTATION; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; HYPERTENSION; NEXT GENERATION SEQUENCING; NOTE; PHENOTYPE; PRIORITY JOURNAL; SMOKING; XANTHOMA;

EID: 84961226154     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2016.03.015     Document Type: Note

References (26)

1. Raal F.J., Santos R.D. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis 2012, 223(2):262-268.
2. Cuchel M., Bruckert E., Ginsberg H.N., Raal F.J., Santos R.D., Hegele R.A., et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur. Heart J. 2014, 35(32):2146-2157.
3. Austin M.A., Hutter C.M., Zimmern R.L., Humphries S.E. Familial hypercholesterolemia and coronary heart disease: a HuGE association review. Am. J. Epidemiol. 2004, 160(5):421-429.
4. Raal F.J., Pilcher G.J., Panz V.R., van Deventer H.E., Brice B.C., Blom D.J., et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation 2011, 124(20):2202-2207.
5. Santos R.D. What are we able to achieve today for our patients with homozygous familial hypercholesterolaemia, and what are the unmet needs?. Atheroscler. Suppl. 2014, 15(2):19-25.
6. Thompson G.R. Managing homozygous familial hypercholesterolaemia from cradle to grave. Atheroscler. Suppl. 2015, 18:16-20.
7. Cuchel M., Meagher E.A., du Toit Theron H., Blom D.J., Marais A.D., Hegele R.A., et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013, 381(9860):40-46.
8. Raal F.J., Santos R.D., Blom D.J., Marais A.D., Charng M.J., Cromwell W.C., et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 375(9719):998-1006.
9. Raal F.J., Honarpour N., Blom D.J., Hovingh G.K., Xu F., Scott R., et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 2015, 385(9965):341-350.
10. Hegele R.A., Ban M.R., Cao H., McIntyre A.D., Robinson J.F., Wang J. Targeted next-generation sequencing in monogenic dyslipidemias. Curr. Opin. Lipidol. 2015, 26(2):103-113.
11. Sjouke B., Kusters D.M., Kindt I., Besseling J., Defesche J.C., Sijbrands E.J., et al. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur. Heart J. 2015, 36(9):560-565.
12. Benn M., Watts G.F., Tybjaerg-Hansen A., Nordestgaard B.G. Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J. Clin. Endocrinol. Metab. 2012, 97(11):3956-3964.
13. Bertolini S., Pisciotta L., Rabacchi C., Cefalu A.B., Noto D., Fasano T., et al. Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy. Atherosclerosis 2013, 227(2):342-348.
14. Raal F, Sjouke B, Hovingh GK, Isaac BF. Phenotype diversity among patients with homozygous familial hypercholesterolemia: a cohort study. Atherosclerosis doi: . http://10.1016/j.atherosclerosis.2016.03.009.
15. Gidding S.S., Ann Champagne M., de Ferranti S.D., Defesche J., Ito M.K., Knowles J.W., et al. The Agenda for Familial Hypercholesterolemia: a scientific statement from the american heart association. Circulation 2015, 132(22):2167-2192.
16. Santos P.C., Morgan A.C., Jannes C.E., Turolla L., Krieger J.E., Santos R.D., et al. Presence and type of low density lipoprotein receptor (LDLR) mutation influences the lipid profile and response to lipid-lowering therapy in Brazilian patients with heterozygous familial hypercholesterolemia. Atherosclerosis 2014, 233(1):206-210.
17. Santos R.D., Frauches T.S., Chacra A.P. Cascade screening in familial hypercholesterolemia: advancing forward. J. Atheroscler. Thromb. 2015, 22(9):869-880.
18. Starr B., Hadfield S.G., Hutten B.A., Lansberg P.J., Leren T.P., Damgaard D., et al. Development of sensitive and specific age- and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing. Clin. Chem. Lab. Med. 2008, 46(6):791-803.
19. Besseling J., Huijgen R., Martin S.S., Hutten B.A., Kastelein J.J., Hovingh G.K. Clinical phenotype in relation to the distance-to-index-patient in familial hypercholesterolemia. Atherosclerosis 2015, 246:1-6.
20. Alonso R., Andres E., Mata N., Fuentes-Jimenez F., Badimon L., Lopez-Miranda J., et al. Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. J. Am. Coll. Cardiol. 2014, 63(19):1982-1989.
21. Jannes C.E., Santos R.D., de Souza Silva P.R., Turolla L., Gagliardi A.C., Marsiglia J.D., et al. Familial hypercholesterolemia in Brazil: cascade screening program, clinical and genetic aspects. Atherosclerosis 2015, 238(1):101-107.
22. Baum S.J., Sijbrands E.J., Mata P., Watts G.F. The doctor's dilemma: challenges in the diagnosis and care of homozygous familial hypercholesterolemia. J. Clin. Lipidol. 2014, 8(6):542-549.
23. Raal F.J., Stein E.A., Dufour R., Turner T., Civeira F., Burgess L., et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 2015, 385(9965):331-340.
24. Sijbrands E.J., Nieman K., Budoff M.J. Cardiac computed tomography imaging in familial hypercholesterolaemia: implications for therapy and clinical trials. Curr. Opin. Lipidol. 2015, 26(6):586-592.
25. Walzer S., Travers K., Rieder S., Erazo-Fischer E., Matusiewicz D. Homozygous familial hypercholesterolemia (HoFH) in Germany: an epidemiological survey. Clin. Outcomes Res. CEOR 2013, 5:189-192.
26. Nordestgaard B.G., Chapman M.J., Humphries S.E., Ginsberg H.N., Masana L., Descamps O.S., et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur. Heart J. 2013, 34(45):3478-3490a.